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Introduction
Patients with systemic lupus erythematosus (SLE) remain 
at increased risk for premature death [1], particularly 
among young adults [2]. Up to 45% of cases present early 
end organ damage, related to persistent activity or kidney 
disease [3]. Renal involvement, which occurs in 40 to 50% 
of patients in most series, is associated with mortality 
rates approximately eight times higher than expected [2], 
and remains only partially responsive to the best available 
treatments. Indeed, therapy with cyclophosphamide has 
not improved patient survival compared with cortico-
steroids [4], and the largest controlled trial comparing 
mycophenolate mofetil with intravenous cyclophospha-
mide in lupus nephritis achieved complete remission in 
only 8.6% and 8.1% of patients, respectively [5]. 
Undoubtedly there is a need for safer and more eﬀ  ective 
treatments for SLE.
Mesenchymal stem cells
Mesenchymal stromal cells, originally described in the 
1960s as bone forming cells in the bone marrow [6], are 
now called multipotent mesenchymal stromal cells, or 
more commonly mesenchymal stem cells (MSCs) since 
they display adult stem cell multipotency. Th  us, they 
diﬀ   erentiate into bone, cartilage and other connective 
tissues [7]. Unlike hematopoietic stem cells, which origi-
nate from bone marrow, MSCs can also be isolated from 
a variety of other tissues, such as umbilical cord or 
adipose tissue, and can be extensively expanded in vitro
by up to 50 cell doublings without diﬀ  erentiation [8].
While these properties initially put MSCs center stage of 
an alleged era of regenerative medicine, the unexpected 
ﬁ   ndings of Bartholomew and colleagues in 2002 [9] 
pointed to new features of these progenitor cells, the 
consequences of which are still being revealed in several 
areas of medicine. MSCs were found to escape T-cell 
recognition, suppress T-cell response to mitogens and 
also to prolong skin graft survival in baboons. In spite of 
a wide array of immunomodulatory eﬀ   ects that were 
subsequently proven to aﬀ   ect T and B lymphocytes, 
natural killer and antigen-presenting cells [10,11], MSCs 
remain hypoimmunogenic since they express low levels 
of major histocompatibility (MHC) class I molecules and 
do not express MHC class II or co-stimulatory (CD40, 
CD40L, CD80 or CD86) molecules [12]. Since the eﬀ  ects 
on immunocompetent cells are not MHC restricted, 
allogenic MSCs are widely used with no need to match 
them with host human leukocyte antigens (HLAs). Th  e 
mechanisms underlying these eﬀ   ects are a subject of 
great scientiﬁ   c interest, as reviewed elsewhere in this 
issue, but apparently involve both cell contact and soluble 
Abstract
Mesenchymal stem cells (MSCs) are now known to 
display not only adult stem cell multipotency but also 
robust anti-infl  ammatory and regenerative properties. 
After widespread in vitro and in vivo preclinical testing 
in several autoimmune disease models, allogenic MSCs 
have been successfully applied in patients with severe 
treatment-refractory systemic lupus erythematosus. 
The impressive results of these uncontrolled phase I 
and II trials - mostly in patients with non-responding 
renal disease - point to the need to perform controlled 
multicentric trials. In addition, they suggest that there 
is much to be learned from the basic and clinical 
science of MSCs in order to reap the full potential of 
these multifaceted progenitor cells in the treatment of 
autoimmune diseases.
© 2010 BioMed Central Ltd
Mesenchymal stem cells for the treatment of 
systemic lupus erythematosus: is the cure for 
connective tissue diseases within connective 
tissue?
Flavio A Carrion1,2 and Fernando E Figueroa*1,2
REVIEW
*Correspondence: ffi   gueroa@uandes.cl
1Laboratorio de Inmunología Celular y Molecular, Facultad de Medicina, 
Universidad de los Andes, Avda San Carlos de Apoquindo 2200, Las Condes, 
Santiago 7620001, Chile
Full list of author information is available at the end of the article
Carrion and Figueroa Stem Cell Research & Therapy 2011, 2:23
http://stemcellres.com/content/2/3/23
© 2011 BioMed Central Ltdfactors, including indoleamine 2,3-dioxygenase, prosta-
glandin E2, nitric oxide, transforming growth factor 
(TGF)-β1, IL-10, soluble HLA-G, and IL-1 receptor anta-
go  nists [13,14]. Also, several growth factors, such as 
hepatocyte growth factor, vascular endothelial growth 
factor (VEGF), insulin-like growth factor, epidermal 
growth factor, basic ﬁ  broblast growth factor and stromal 
cell-derived factor-1, among others, have been implicated 
in the modulatory and reparative eﬀ  ects of MSCs [15].
Recently, several studies have identiﬁ  ed critical roles 
for microRNAs (miRNAs) involved in proliferation, 
migration and diﬀ  erentiation of MSCs, suggesting that 
they might play an important role in the acquisition of 
reparative MSC phenotypes [16].
Therapeutic use of MSCs in autoimmune and 
infl  ammatory diseases
Given their vast proliferative potential, extensive immuno-
suppressive properties, and also the ease of access to 
proper tissue sources, therapies with autologous or 
allogenic MSCs have been tested in a variety of immune-
mediated disease models, including experimental allergic 
encephalomyelitis [17,18] - a model of multiple sclerosis - 
diabetic NOD/SCID mice [19], collagen-induced arthritis 
[20,21], and several lupus murine models [22-28]. Results 
have been mainly encouraging, but not altogether consis-
tent, particularly in the case of arthritis [29], and lupus 
mice [26,27].
At the time of writing this review, 141 registered 
human trials on MSCs were found at the National Insti-
tutes of Health ClinicalTrials.gov website [30], including 
13 for graft versus host disease (GVHD), 10 for diabetes, 
7 for Crohn’s disease or ulcerative colitis, 5 for multiple 
sclerosis, 2 for amyotrophic lateral sclerosis, one each for 
Sjögren syndrome and systemic sclerosis and two for 
SLE. Some of these trials point to non-immune-mediated 
conditions that are associated with tissue injury, such as 
hepatic cirrhosis, myocardial infarction or congestive 
heart failure. In several instances it has become apparent 
that MSCs are not necessarily replacing diseased tissues 
or diﬀ  erentiating into separate cell lineages, but seem to 
exert a complex pattern of trophic, regenerative and anti-
inﬂ  ammatory eﬀ  ects [31,32].
In humans, the most studied application for MSCs is 
GVHD, a complication of hematopoietic stem cell trans-
plan  tation in which donor T cells attack an immuno-
compromised and genetically disparate recipient [33]. In 
2004, Le Blanc and colleagues [34] treated a 9-year-old 
boy with severe treatment-resistant acute GVHD of the 
gut and liver with third party haplo-identical mother-
derived MSCs. Clinical response was striking, with 
improvement of liver and intestinal function. Th  e most 
recent placebo controlled trials conﬁ  rmed the signiﬁ  cant 
improvement in liver and gastrointestinal GVHD, but did 
not reach signiﬁ  cance for durable complete responses or 
other primary endpoints [35].
Mesenchymal stem cells in systemic lupus 
erythematosus
Perhaps the most remarkable results for human MSC 
therapy are now emerging from the latest clinical trials in 
severe, treatment-refractory SLE [36,37]. While these are 
still small, uncontrolled and non-multicentric studies, the 
recent reports of successful MSC treatment in other 
inﬂ  ammatory and scarring conditions that are typical of 
the SLE spectrum [38,39] lend support to these 
notoriously favorable outcomes. Th   ese trials also 
highlight the need to advance the clinical science of stem 
cell therapy and underscore the challenge of identifying 
speciﬁ   c mechanisms of action, given the multi-tiered 
eﬀ  ects of cellular therapies in vivo [40].
While in the past the connective tissue was assigned a 
low rank among organized tissues, nowadays it seems to 
harbor far reaching properties. Undoubtedly, when Dr 
Paul Klemperer suggested that the histopathological 
connective tissue changes found in SLE were common to 
the ‘obscure maladies that collectively are called diseases 
of the connective tissue or collagen diseases’ [41], little 
did he know that a cure for such diseases might also be 
found within connective tissues!
Animal models of disease
While the MSCs derived from SLE patients and diseased 
mice are still immunosupressive in vitro [42], they are 
abnormal in terms of phenotype, proliferation and diﬀ  er-
entiation [43-45]. Sun and colleagues have forwarded the 
hypothesis that an impaired bone marrow MSC niche 
contributes to disease development in human [43] and 
murine SLE [23]. Th   ey describe in Fas-deﬁ  cient MLR/lpr 
mice a signiﬁ  cant osteoporosis phenotype with osteoclast 
activity and T cell over-activation that does not respond 
to cyclophosphamide treatment, but is corrected by MSC 
transplant [23]. Even if this assumed MSC deﬁ  ciency is 
only a consequence of immune activation in SLE, this 
rationale has supported the use of allo- or xenogeneic - 
instead of autologous - MSCs for the treatment of SLE 
[23]. For example, in MRL/lpr mice, allogenic mouse or 
human MSCs derived from bone marrow (BM-MSCs), 
umbilical cord (UC-MSCs) or exfoliated deciduous teeth 
have all been highly eﬀ   ective in reducing or even 
normalizing serum autoantibodies, proteinuria, renal 
pathology and survival of diseased animals [22-25]. In 
contrast, the NZB/W F1 strain, considered the murine 
model that most closely resembles human SLE, has 
shown diverging results. For example, human UC-MSCs 
delayed disease and alleviated lupus nephritis [27], while 
allogenic murine BM-MSCs (from C57BL/6J mice) did 
not aﬀ  ect proteinuria or double-stranded DNA (dsDNA) 
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BM-MSCs from another strain (BALB/c mice) had 
opposite eﬀ  ects, enhancing anti-dsDNA antibody pro  duc-
tion and worsening disease and kidney pathology [26].
Human systemic lupus erythematosus
Prompted by the positive results in the Fas-deﬁ  cient 
MRL/lpr mice treated with human MSCs from healthy 
individuals [22], Sun and colleagues [23] treated four 
patients with active disease and lupus nephritis (24 hour 
urine protein ≥1 g and/or serum creatinine ≥1.5 mg/dl) 
that was unresponsive to monthly intravenous cyclo-
phos  phamide (0.75 g/m2) and oral prednisone (≥20 mg/
day) for 6 months. All patients received one infusion of 
≥1 × 106 BM-MSCs (from healthy family members) per 
kilogram of body weight. Th  e Systemic Lupus Disease 
Activity Index (SLEDAI) at 1, 6 and 12 months follow-up 
improved signiﬁ  cantly, as did urinary protein, and also 
CD4+ Foxp3+ T regulatory (Treg) cell counts at 3 months 
follow-up. Prednisone and cyclophosphamide were 
reduced, and the latter even suspended in two patients. 
None had complications after 12 to 18 months follow-up. 
Th  ese encouraging results led to a larger phase I open 
trial in 15 patients - including the ﬁ  rst 4 cases reported - 
with refractory disease as described above, except that 
one-third of patients had also failed oral mycophenolate 
mophetil (1 to 2 g/day for 3 months) [37]. All cases 
fulﬁ  lled the previously stated criteria for refractory renal 
disease except one with only refractory thrombo  cyto-
penia (24 × 109/L). Non-renal manifesta  tions included 
arthritis, severe skin disease, serositis and ten cases with 
non-responsive cytopenias. Patients received one intra-
venous infusion of 1 × 106 allogeneic BM-MSCs per 
kilogram body weight (harvested from passages 3 to 5) 
from non-HLA-matched healthy family members. Subse-
quently, steroids were reduced to 5 to 10 mg/day main-
tain  ing lower dose cyclophosphamide (0.4 to 0.6 g) for 2 
to 3 months. Mean follow-up reached 17.2 (3 to 36) months 
with no adverse eﬀ   ects, deaths or ensuing GVHD. 
Clinical and serological changes were quite dramatic for 
this group of patients with severe disease as gauged by an 
average baseline SLEDAI of 12.1 ± 3.3, in spite of daily 
prednisone (23 ± 5 mg) and immunosuppressive drugs. 
In 12 patients SLEDAI again improved signiﬁ  cantly, to 
3.2 ± 2.8 at 12 months (P < 0.05), remaining under 8 in all 
patients and even zero in four patients. Only one subject 
was able to discontinue immunosuppressants, remaining 
with inactive disease at 12 months on 5 mg daily 
prednisone. Two patients ﬂ   ared at 6 and 12 months, 
respectively. Quite surprisingly, 24  hour proteinuria 
(2,538.0 ± 382.3 mg at baseline) decreased signiﬁ  cantly 
(1,430.7 ± 306.3; P < 0.01, n = 12) as soon as one week 
after MSC therapy - even preceding changes in anti-
dsDNA antibodies - and continued to improve thereafter 
until month 12. Glomerular ﬁ  ltration rate improved in 
two patients who had reduced values at study entry, as 
did creatinine levels in four subjects. Anti-dsDNA 
antibodies decreased signiﬁ  cantly at 1 month (P < 0.05) 
and 3 months (P < 0.05) post-transplant. Treg cells, which 
have been found to be quantitatively and qualitatively 
deﬁ  cient in active SLE [46,47], were restored at week 1 
(from 2.56 ± 0.37 to 4.58 ± 0.51; P < 0.05, n = 13) as 
judged by the percentage of CD4+ Foxp3+ cells among 
peripheral blood mononuclear cells.
A second open trial from this group in Nanjing, China 
followed, reporting the use of UC-MSCs in severe lupus 
[36]. UC-MSCs are easily accessible, have high prolifera-
tive potential [48] and have been used with success in 
lupus mice [24]. Patients (n = 16) and entry criteria were 
similar to the previous study, though this time 5 of 15 
renal cases had histological conﬁ  rmation of proliferative 
nephritis, and 11 were preconditioned with cyclophos-
pha  mide (0.8 to 1.8 g intravenously) prior to MSC 
infusion. Subsequently, prednisone was reduced to 5 to 
10 mg every 2 weeks and patients were kept on mainte-
nance cyclophosphamide (0.6 to 0.8 g), which was able to 
be eventually discontinued in only three individuals. 
Mean follow-up was only 8.25 months. Signiﬁ  cant im-
prove  ment at 1 and/or 3 months was veriﬁ  ed by SLEDAI 
score (two patients completed 2 years with scores <4), 
serum albumin, 24 hour urinary protein, serum creati-
nine (six patients), serum C3 (ﬁ   ve patients) and anti-
dsDNA antibodies. Baseline CD4+ Foxp3+ cells (Treg 
cells) increased signiﬁ  cantly at 3 and 6 months, and a fall 
in serum IL-4 (with a non-signiﬁ  cant increase of IFN-γ) 
was interpreted by the authors as indicative of improve-
ment of pathogenic Th   2 imbalance, though animal lupus 
models have shown the opposite cytokine change [27]. 
Finally, a case report from the group in Nanjing, but not 
from the realm of renal disease, draws further attention 
to the potency of MSC treatment: a 19-year-old girl with 
a recent diagnosis of SLE presented with massive diﬀ  use 
alveolar hemorrhage unresponsive to methylprednisolone 
(160 mg/d for 4 days, 500 mg/d for 3 days) and 
intravenous immunoglobulin (20 g/day for 5 days) [49]. 
Repeated high-resolution chest computed tomography 
spanning 9 weeks showed diﬀ  use bilateral alveolar inﬁ  l-
trates. After only one day of UC-MSC infusion (2 × 106/kg 
body weight) the patient’s level of oxygen saturation rose 
from 71 to 91%, and 5 days later mechanical respiratory 
support was removed. Nine days later high-resolution 
chest computed tomography showed complete resolu-
tion. Recurrent pulmonary disease 6 weeks after being 
discharged - while on prednisone, cyclophosphamide and 
cyclosporin A - again responded promptly to MSC re-
treatment. Th  is dramatic case underscores the need to 
unravel the biological components underlying the clinical 
eﬀ  ects of MSCs.
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treatment
Despite the in vitro and in vivo evidence for a therapeutic 
eﬀ  ect of MSCs in SLE, the mechanisms by which MSCs 
exert their immunomodulatory and reparative eﬀ  ects are 
still incompletely understood, but most likely involve 
multiple mechanisms (Figure 1).
Proinfl  ammatory ‘licensing’ of MSCs
In contrast to therapies that cause global immune 
suppression, MSCs have been dubbed ‘smart’ immune 
modulators since their suppressive eﬀ   ects require a 
previous ‘licensing’ step that occurs in the presence of an 
inﬂ   ammatory environment, and is mediated by the 
secretion of speciﬁ  c cytokines [50]. Th   us, IFN-γ, alone or 
together with tumor necrosis factor-α, IL-1α or IL-1β, are 
required to provoke the expression by MSCs of high 
levels of soluble factors involved in immunosuppression, 
such as indoleamine 2,3-dioxygenase, hepatocyte growth 
factor, TGF-β1 and nitric oxide [51-54]. Th   e need for this 
activation step has been conﬁ  rmed in a model of GVHD 
since recipients of IFN-γ-/- T cells did not respond to 
MSC treatment evolving into fatal GVHD [55].
Tipping of the Th1/Th2 balance
Although still controversial, an imbalance in IFN-γ and 
IL-4 cytokine levels, suggestive of a pathogenic T helper 
2 (Th   2) response, has been reported in SLE. Accordingly, 
Figure 1. Systemic administration of mesenchymal stem cells can trigger distal (endocrine) or local (paracrine) eff  ects that include 
cell-mediated actions. 1) Promotion of angiogenesis: vascular endothelial growth factor (VEGF), insulin like growth factor 1 (IGF-1), monocyte 
chemoatractant protein 1 (MCP-1), basic fi  broblast growth factor (bFGF) and interleukin 6 (IL-6). 2) Stem cell growth and diff  erentiation: stem 
cell factor (SCF), leukemia-inhibitory factor (LIF), macrophage colony-stimulating factor (M-CSF), stromal derived factor 1 (SDF-1), angiopoietin 
1 and activin A. 3) Inhibition of fi  brosis: hepatocyte growth factor (HGF), bFGF, adrenomedullin (ADM). 4) Inhibition of apoptosis: VEGF, HGF, 
IGF-1, transforming growth factor (TGF)-β, bFGF, granulocyte macrophage colony-stimulating factor (GM-CSF), activin A and thrombospondin-1. 
Immune mediated eff  ects include the following (5 to 8). 5) Suppression of T and B cells: human leukocyte antigen G5 (HLA-G5), HGF, inducible 
nitric oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 (PGE-2), bFGF and TGF-β. 6) Induction of regulatory T cell (Treg) 
diff  erentiation and expansion by TGF-β expression. 7) Inhibition of natural killer (NK) cells by secretion of IDO, PGE-2 and TGF-β. 8) Inhibition of 
dendritic cell (DC) maturation by secretion of PGE-2. iDC, immature dendritc cells; mDC, mature dendritic cells.
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ameliorate SLE by promoting the conversion from a Th  2 
humoral response to a Th  1 cellular immune response 
through modulation of IL-4 and IFN-γ levels in eﬀ  ector 
T cells. Zhou and colleagues [22] showed that intraperi-
to  neal infusion of human BM-MSCs in MRL/lpr mice 
decreased the production of IL-4 and increased IFN-γ in 
peripheral blood T cells. Sun and colleagues [36] 
reported similar ﬁ  ndings with UC-MSC transplantation 
in patients with refractory SLE 3 months after treatment, 
also suggesting a polarization toward a Th  1 phenotype 
that was associated with clinical improvement. However, 
Aggarwal and Pittenger [51] showed the opposite eﬀ  ect 
with the addition of human MSCs to diﬀ  erentiated 
eﬀ  ector T cells in vitro, and Chang and colleagues [27] 
found that UC-MSC transplantation in NZB/W F1 mice 
was associated with an increase in the Th   2 phenotype in 
the face of improving disease. Th   e divergent results from 
these studies underline the complexity of both MSC-
mediated eﬀ  ects and the immunopathogenesis of SLE.
Eff  ects on CD4+ T cell populations: upregulation of 
Treg/Th17 ratio
Several studies have provided evidence of a quantitative 
and/or qualitative defect of Treg cells in human SLE, as 
well as an increased production of Th  17  proinﬂ  ammatory 
cells [46-47,56]. On the other hand, MSCs have been 
shown to induce the generation of functional Treg cells 
both in vitro and in vivo [21,57,58]. In MLR/lpr mice, the 
transplantation of MSCs from many sources (bone 
marrow, umbilical cord or exfoliated deciduous teeth), 
can restore Treg cells and induce a signiﬁ  cant reduction 
in Th  17 levels, consequently up-regulating the ratio of 
Treg/Th  17 cells [23-25]. In human SLE, the transplan-
tation of either allogeneic or autologous MSCs derived 
from bone marrow or umbilical cord also increases Treg 
cells, suggesting that this may be one of the mechanisms 
of the MSC-mediated improvement of disease [23,36,37]. 
However, in two patients with active but not highly 
inﬂ   ammatory SLE, we reported that the infusion of 
autologous MSCs induced no amelioration in spite of 
generating a marked increase in Treg cells [59].
Mesenchymal stem cell homing and diff  erentiation
Long-term persistence of autologous or allogenic MSCs 
after a single intravenous infusion has been described in 
baboons, with levels of tissue engraftment ranging from 
0.1 to 2.7% [60]. However, in a chronic kidney disease 
model, only repeated injections were associated with 
functional improvement and cortical entrapment of 
MSCs at 5 weeks [39]. In NZB/W F1 lupus mice treated 
with 1 × 106 human UC-MSCs via the tail vein, Chang 
and colleagues [27] could evidence MSCs in kidney tissues 
at week 2 of infusion, but no long-term engraftment. 
Even if MSCs protect and improve recovery from several 
models of acute and chronic renal injury [61,62], 
paracrine and endocrine eﬀ   ects seem most important, 
since con  ditioned medium from MSCs has been able to 
mimic the beneﬁ  cial eﬀ  ects of stem cell therapy [63]. Th  e 
intricacy of such endocrine factors in vivo has been 
elegantly illustrated by Lee and colleagues [64] in a 
mouse model in which the reduced size of myocardial 
infarction in response to the infusion of human MSCs 
was due to the secretion of the anti-inﬂ  ammatory protein 
TSG-6 triggered by MSC entrapment in the lung.
Gene expression and growth factors
A number of genes and growth factors responsible for 
renal regeneration also seem to be involved in renal 
repair after the administration of MSCs [38]. High levels 
of angiogenic factors, such as VEGF, have been related to 
glomerulonephritis in SLE [65,66], and Zhou and 
colleagues [22] showed that transplantation of human 
BM-MSCs in MRL/lpr mice reduced the expression of 
VEGF and TGF-β and also deposits of ﬁ  bronectin  in 
glomeruli. In an ischemic model of chronic kidney 
disease we have shown that a single intravenous infusion 
of autologous MSCs triggers a signiﬁ  cant increase in a 
group of nephrogenic proteins and transcription factors 
related to endothelial (VEGF and the angiopoietin-1 
receptor Tie-2) and epithelial (bone morphogenetic 
protein-7, Pax-2, and basic ﬁ   broblast growth factor) 
diﬀ  er  entiation, in association with a marked improve-
ment of renal function [67].
Additionally, the importance of epigenetic regulatory 
factors in the control of biological processes and of the 
immune response has also been stressed. Common 
miRNA patterns of expression have been found in three 
diﬀ  erent murine models of SLE [68], suggesting these 
might be targeted therapeutically. Since MSCs have been 
shown to secrete microparticles enriched in miRNAs 
[69], several authors have suggested that microvesicle-
mediated transfer of mRNA from MSCs to target tissues 
might also participate in some of the processes involved 
in immunoregulation or in the recovery from kidney 
injury in response to stem cell treatment [70].
Conclusion
Th   e results of the ﬁ  rst clinical trials with MSC therapy in 
severe SLE are undoubtedly encouraging. However, the 
heterogeneity of MSCs as deﬁ  ned today and the intricate 
circuitry of cellular and humoral factors that mediate 
their presently known eﬀ  ects still point to many issues to 
be resolved in order to pave the way for cell therapy in 
SLE. Long-term safety concerns remain an issue, given 
the description of in vitro malignant MSC transformation 
[71] and the unknown interaction of regular immuno-
supressants with single or repeated MSC therapy [72]. 
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clinical trials, future advances from stem cell science can 
be expected to pinpoint signiﬁ  cant MSC subpopulations 
and/or stem cell markers for regenerative or immuno-
regulatory properties, as well as speciﬁ  c mechanisms of 
action [73]. Th  us, assays for in vitro or in vivo MSC 
potency could be developed, leading the way to the use of 
more potent stimulated or primed pre-treated MSCs.
Abbreviations
BM-MSC, bone marrow-derived mesenchymal stem cell; dsDNA, double-
stranded DNA; GVHD, graft versus host disease; HLA, human leukocyte 
antigen; IFN, interferon; IL, interleukin; MHC, major histocompatibility 
complex; miRNA, microRNA; MSC, mesenchymal stem cell; SLE, systemic 
lupus erythematosus; SLEDAI, Systemic Lupus Disease Activity Index; TGF, 
transforming growth factor; Th, T helper; Treg, T regulatory; UC-MSC, umbilical 
cord-derived mesenchymal stem cell; VEGF, vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Both authors contributed to the writing of the manuscript and read and 
approved the fi  nal version.
Acknowledgements
The authors thank Dr Felipe Alablaza for his contribution to the design of the 
fi  gure. This work was supported by grant MED-004-7 from Universidad de los 
Andes and grant Innova Chile Corfo 205-4350.
Author details
1Laboratorio de Inmunología Celular y Molecular, Facultad de Medicina, 
Universidad de los Andes, Avda San Carlos de Apoquindo 2200, Las Condes, 
Santiago 7620001, Chile. 2Programa de Terapia Celular, Facultad de Medicina, 
Universidad de los Andes, Avda San Carlos de Apoquindo 2200, Las Condes, 
Santiago 7620001, Chile.
Published: 11 May 2011
References
1.  Sacks JJ, Helmick CG, Langmaid G, Sniezek JE: Trends in deaths from 
systemic lupus erythematosus US 1979-1998. MMWR Morb Mortal Wkly Rep 
2002, 51:371-374.
2.  Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, 
Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, 
Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer 
M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy 
H, McCarthy T, et al.: Mortality in systemic lupus erythematosus. Arthritis 
Rheum 2006, 54:2550-2557.
3.  Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, 
Marchesoni A, Mosca M, Påi S, Manger K, Schneider M, Nielsen H, van 
Vollenhoven R, Swaak T: Disease activity and damage accrual during the 
early disease course in a multinational inception cohort of patients with 
systemic lupus erythematosus. Lupus 2010, 19:949-956.
4.  Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, 
Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: 
Combination therapy with pulse cyclophosphamide plus pulse 
methylprednisolone improves long-term renal outcome without adding 
toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
5.  Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, 
Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D: Aspreva Lupus 
Management Study Group. Mycophenolate mofetil versus 
cyclophosphamide for induction treatment of lupus nephritis. J Am Soc 
Nephrol 2009, 20:1103-1112.
6.  Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV: Osteogenesis in 
transplants of bone marrow cells. J Embryol Exp Morphol 1966, 16:381-390.
7.  Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, 
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of 
adult human mesenchymal stem cells. Science 1999, 284:143-147.
8.  Welter JF, Solchaga LA, Penick KJ: Simplifi  cation of aggregate culture of 
human mesenchymal stem cells as a chondrogenic screening assay. 
Biotechniques 2007, 42:732-737.
9.  Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, 
Devine S, Ucker D, Deans R, Moseley A, Hoff  man R: Mesenchymal stem cells 
suppress lymphocyte proliferation in vitro and prolong skin graft survival 
in vivo. Exp Hematol 2002, 30:42-48.
10.  Uccelli A, Moretta L, Pistoia V: Immunoregulatory function of mesenchymal 
stem cells. Eur J Immunol 2006, 36:2566-2573.
11.  Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, 
Jorgensen C, Le Blanc K, Luyten F, McGonagle D, Martin I, Bocelli-Tyndall C, 
Pennesi G, Pistoia V, Pitzalis C, Uccelli A, Wulff  raat N, Feldmann M: 
Immunomodulatory properties of mesenchymal stem cells: a review 
based on an interdisciplinary meeting held at the Kennedy Institute of 
Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 
2007, 9:301.
12.  Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: mesenchymal 
stem cells: their phenotype, diff  erentiation capacity, immunological 
features, and potential for homing. Stem Cells 2007, 25:2739-2749.
13.  Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal 
stromal cells. Blood 2007, 110:3499-3506.
14.  Ghannam S, Bouffi    C, Djouad F, Jorgensen C, Noël D: Immunosuppression 
by mesenchymal stem cells: mechanisms and clinical applications. Stem 
Cell Res Ther 2010, 1:2.
15.  Burdon T, Paul A, Noiseux N, Prakash S, Shum-Tim D: Bone marrow stem cell 
derived paracrine factors for regenerative medicine: current perspectives 
and therapeutic potential. Bone Marrow Res 2011. doi: 10.1155/2011/207326.
16.  Tome M, López-Romero P, Albo C, Sepúlveda JC, Fernández-Gutiérrez B, 
Dopazo A, Bernad A, González MA: miR-335 orchestrates cell proliferation, 
migration and diff  erentiation in human mesenchymal stem cells. Cell 
Death Diff  er 2010. doi:10.1038/cdd.2010.167.
17.  Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, 
Yuan S, Young YK, Boivin MN, Forner K, Basik M, Galipeau J: Mesenchymal 
stromal cells ameliorate experimental autoimmune encephalomyelitis by 
inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent 
manner. J Immunol 2009, 182:5994-6002.
18.  Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH: Human 
bone marrow derived mesenchymal stem cells induce Th2-polarized 
immune response and promote endogenous repair in animal models of 
multiple sclerosis. Glia 2009, 57:1192-1203.
19.  Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ: 
Multipotent stromal cells from human marrow home to and promote 
repair of pancreatic islets and renal glomeruli in diabetic NOD/SCID mice. 
Proc Natl Acad Sci U S A 2006, 103:17438-17443.
20.  Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G: Cell therapy using 
allogeneic bone marrow mesenchymal stem cells prevents tissue damage 
in collagen-induced arthritis. Arthritis Rheum 2007, 56:1175-1186.
21.  González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M: Treatment of 
experimental arthritis by inducing immune tolerance with human 
adipose-derived mesenchymal stem cells. Arthritis Rheum 2009, 
60:1006-1019.
22.  Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L: Transplantation of 
human bone marrow mesenchymal stem cell ameliorates the 
autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008, 
5:417-424.
23.  Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S: 
Mesenchymal stem cell transplantation reverses multiorgan dysfunction 
in systemic lupus erythematosus mice and humans. Stem Cells 2009, 
27:1421-1432.
24.  Gu Z, Akiyama K, Ma X, Zhang H, Feng X, Yao G, Hou Y, Lu L, Gilkeson GS, 
Silver RM, Zeng X, Shi S, Sun L: Transplantation of umbilical cord 
mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus 
2010, 19:1502-1514.
25.  Yamaza T, Kentaro A, Chen C, Liu Y, Shi Y, Gronthos S, Wang S, Shi S: 
This article is part of a review series on Immunology and stem cells, 
edited by Christian Jorgensen. Other articles in the series can be 
found online at http://stemcellres.com/series/immunology
Carrion and Figueroa Stem Cell Research & Therapy 2011, 2:23
http://stemcellres.com/content/2/3/23
Page 6 of 8Immunomodulatory properties of stem cells from human exfoliated 
deciduous teeth. Stem Cell Res Ther 2010, 1:5.
26.  Youd M, Blickarz C, Woodworth L, Touzjian T, Edling A, Tedstone J, Ruzek M, 
Tubo R, Kaplan J, Lodie T: Allogeneic mesenchymal stem cells do not 
protect NZBxNZW F1 mice from developing lupus disease. Clin Exp 
Immunol 2010, 161:176-186.
27.  Chang JW, Hung SP, Wu HH, Wu WM, Yang AH, Tsai HL, Yang LY, Lee OK: 
Therapeutic eff  ects of umbilical cord blood-derived mesenchymal stem 
cell transplantation in experimental lupus nephritis. Cell Transplant 2010. 
doi: 10.3727/096368910X520056.
28.  Schena F, Gambini C, Gregorio A, Mosconi M, Reverberi D, Gattorno M, 
Casazza S, Uccelli A, Moretta L, Martini A, Traggiai E: Interferon-γ-dependent 
inhibition of B cell activation by bone marrow-derived mesenchymal stem 
cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 
2010, 62:2776-2786.
29.  Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P: Discrepancy 
between the in vitro and in vivo eff  ects of murine mesenchymal stem cells 
on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010, 
12:R31.
30.  ClinicalTrials.gov [http://clinicaltrials.gov/ct2/results?term=msc]
31.  Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, DiMattia G, 
Sullivan DE, Prockop DJ: Multipotent stromal cells are activated to reduce 
apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem 
Cells 2009, 27:670-681.
32.  Chen L, Tredget EE, Wu PY, Wu Y: Paracrine factors of mesenchymal stem 
cells recruit macrophages and endothelial lineage cells and enhance 
wound healing. PLoS One 2008, 3:e1886.
33.  English K, French A, Wood KJ: Mesenchymal stromal cells: facilitators of 
successful transplantation? Cell Stem Cell 2010, 7:431-442.
34.  Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, 
Ringdén O: Treatment of severe acute graft-versus-host disease with third 
party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
35.  Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III 
GVHD Trials [http://investor.osiris.com/releasedetail.cfm?releaseID=407404]
36.  Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu 
W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S: Umbilical cord 
mesenchymal stem cell transplantation in severe and refractory systemic 
lupus erythematosus. Arthritis Rheum 2010, 62:2467-2475.
37.  Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun 
L: Allogenic mesenchymal stem cells transplantation in refractory 
systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 
69:1423-1429.
38.  Tögel FE, Westenfelder C: Mesenchymal stem cells: a new therapeutic tool 
for AKI. Nat Rev Nephrol 2010, 6:179-183.
39.  Lee SR, Lee SH, Moon JY, Park JY, Lee D, Lim SJ, Jeong KH, Park JK, Lee TW, Ihm 
CG: Repeated administration of bone marrow-derived mesenchymal stem 
cells improved the protective eff  ects on a remnant kidney model. Ren Fail 
2010, 32:840-848.
40.  Singer NG, Caplan AI: Mesenchymal stem cells: mechanisms of 
infl  ammation. Annu Rev Pathol Mech Dis 2011, 6:457-478.
41. Klemperer  P:  The concept of connective tissue diseases. Circulation 1962, 
25:869-871.
42.  Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, 
Pistoia V, Martin I, Tyndall A: Bone marrow mesenchymal stromal cells 
(BM-MSCs) from healthy donors and auto-immune disease patients 
reduce the proliferation of autologous- and allogeneic-stimulated 
lymphocytes in vitro. Rheumatology (Oxford) 2007, 46:403-408.
43.  Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM: Abnormality of bone 
marrow-derived mesenchymal stem cells in patients with systemic lupus 
erythematosus. Lupus 2007, 16:121-128.
44.  Nie Y, Lau C, Lie A, Chan G, Mok M: Defective phenotype of mesenchymal 
stem cells in patients with systemic lupus erythematosus. Lupus 2010, 
19:850-859.
45.  El-Badri NS, Hakki A, Ferrari A, Shamekh R, Good RA: Autoimmune disease: 
is it a disorder of the microenvironment? Immunol Res 2008, 411:79-86.
46.  La Cava A: T-regulatory cells in systemic lupus erythematosus. Lupus 2008, 
17:421-425.
47.  Valencia X, Yarboro C, Illei G, Lipsky PE: Defi  cient CD4+CD25high T 
regulatory cell function in patients with active systemic lupus 
erythematosus. J Immunol 2007, 178:2579-2588.
48.  Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, 
Chen ZZ, Han ZC: Isolation and characterization of human umbilical cord 
mesenchymal stem cells with hematopoiesis-supportive function and 
other potentials. Haematologica 2006, 91:1017-1026.
49.  Liang J, Gu F, Wang H, Hua B, Hou Y, Shi S, Lu L, Sun L: Mesenchymal stem 
cell transplantation for diff  use alveolar hemorrhage in SLE. Nat Rev 
Rheumatol 2010, 6:486-489.
50.  Jones S, Horwood N, Cope A, Dazzi F: The antiproliferative eff  ect of 
mesenchymal stem cells is a fundamental property shared by all stromal 
cells. J Immunol 2007, 179: 2824-2831.
51.  Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood 2005, 105:1815-1822.
52.  Ryan JM, Barry F, Murphy JM, Mahon BP: Interferon-gamma does not break, 
but promotes the immunosuppressive capacity of adult human 
mesenchymal stem cells. Clin Exp Immunol 2007, 149:353-363.
53.  Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, 
Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, 
Annunziato F: Role for interferon-gamma in the immunomodulatory 
activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 
24:386-398.
54.  Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y: 
Mesenchymal stem cellmediated immunosuppression occurs via 
concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 
2:141-150.
55.  Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, 
Mehrotra S, Setty S, Smith B, Bartholomew A: IFN-gamma activation of 
mesenchymal stem cells for treatment and prevention of graft versus host 
disease. Eur J Immunol 2008, 38:1745-1755.
56.  Crispín JC, Tsokos GC: Interleukin-17-producing T cells in lupus. Curr Opin 
Rheumatol 2010, 22:499-503.
57.  Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A: Generation of CD4+ 
or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte 
interaction. Haematologica 2007, 92:881-888.
58.  Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-Cortes P, Rico L, 
Büscher D, Delgado M: Human adipose-derived mesenchymal stem cells 
reduce infl  ammatory and T cell responses and induce regulatory T cells 
in vitro in rheumatoid arthritis. Ann Rheum Dis 2010, 69:241-248.
59.  Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, Mönckeberg G, Figueroa 
FE: Autologous mesenchymal stem cell treatment increased T regulatory 
cells with no eff  ect on disease activity in two systemic lupus 
erythematosus patients. Lupus 2010, 19:317-322.
60.  Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoff  man R: Mesenchymal 
stem cells distribute to a wide range of tissues following systemic infusion 
into nonhuman primates. Blood 2003, 101:2999-3001.
61.  Humphreys BD, Bonventre JV: Mesenchymal stem cells in acute kidney 
injury. Annu Rev Med 2008, 59:311-325.
62.  Choi S, Park M, Kim J, Hwang S, Park S, Lee Y: The role of mesenchymal stem 
cells in the functional improvement of chronic renal failure. Stem Cells Dev 
2009, 18:521-529.
63.  Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG: Stromal cells protect 
against acute tubular injury via an endocrine eff  ect. J Am Soc Nephrol 2007, 
18:2486-2496.
64.  Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, 
Delafontaine P, Prockop DJ: Intravenous hMSCs improve myocardial 
infarction in mice because cells embolized in lung are activated to secrete 
the anti-infl  ammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
65.  Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T: Serum levels 
of angiogenic cytokines in systemic lupus erythematosus and their 
correlation with disease activity. Eur Cytokine Netw 2001, 12:445-452.
66.  Navarro C, Candia-Zúñiga L, Silveira LH, Ruiz V, Gaxiola M, Avila MC, Amigo 
MC: Vascular endothelial growth factor plasma levels in patients with 
systemic lupus erythematosus and primary antiphospholipid syndrome. 
Lupus 2002, 11:21-24.
67.  Villanueva S, Ewertz E, Carrión F, Tapia A, Vergara V, Céspedes C, Saez P, Luz P, 
Irarrázabal C, Carreño JE, Figueroa F, Vio C: Mesenchyaml stem cells 
treatment induces functional and morphological improvement in chronic 
renal failure model in rats. Clin Sci 2011, in press.
68.  Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, Ahmed SA: Identifi  cation 
of a common lupus disease-associated microRNA expression pattern in 
three diff  erent murine models of lupus. PLoS One 2010, 5:e14302.
69.  Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK: Mesenchymal stem cell 
secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res 2010, 
Carrion and Figueroa Stem Cell Research & Therapy 2011, 2:23
http://stemcellres.com/content/2/3/23
Page 7 of 838:215-224.
70.  Camussi G, Deregibus MC, Tetta C: Paracrine/endocrine mechanism of stem 
cells on kidney repair: role of microvesicle-mediated transfer of genetic 
information. Curr Opin Nephrol Hypertens 2010, 19:7-12.
71.  Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, 
Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S: Accumulated 
chromosomal instability in murine bone marrow mesenchymal stem cells 
leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
72.  Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff   M, 
Marini F: Mesenchymal stem cell transition to tumor-associated fi  broblasts 
contributes to fi  brovascular network expansion and tumor progression. 
PLoS One 2009, 4:e4992.
73.  Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S, Worthley SG, Gronthos S, 
Zannettino AC: Enrichment for STRO-1 expression enhances the 
cardiovascular paracrine activity of human bone marrow-derived 
mesenchymal cell populations. J Cell Physiol 2010, 223:530-540.
doi:10.1186/scrt64
Cite this article as: Carrion FA, Figueroa FE: Mesenchymal stem cells for 
the treatment of systemic lupus erythematosus: is the cure for connective 
tissue diseases within connective tissue? Stem Cell Research & Therapy 2011, 
2:23.
Carrion and Figueroa Stem Cell Research & Therapy 2011, 2:23
http://stemcellres.com/content/2/3/23
Page 8 of 8